{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:00:32Z","timestamp":1793048432401,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11427-024-2760-4","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T03:25:17Z","timestamp":1737775517000},"page":"1676-1688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Synergistic effects of mTOR inhibitors with VEGFR3 inhibitors on the interaction between TSC2-mutated cells and lymphatic endothelial cells"],"prefix":"10.1007","volume":"68","author":[{"given":"Hanghang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danjing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongsheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"2760_CR1","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1158\/1535-7163.MCT-11-0866-T","volume":"11","author":"A Alam","year":"2012","unstructured":"Alam, A., Blanc, I., Gueguen-Dorbes, G., Duclos, O., Bonnin, J., Barron, P., Laplace, M. C., Morin, G., Gaujarengues, F., Dol, F., et al. (2012). SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities. Mol Cancer Ther 11, 1637\u20131649.","journal-title":"Mol Cancer Ther"},{"key":"2760_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4161\/cc.27355","volume":"13","author":"A Alayev","year":"2014","unstructured":"Alayev, A., Sun, Y., Snyder, R., Malka Berger, S., Yu, J., and Holz, M. (2014). Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells. Cell Cycle 13, 371\u2013382.","journal-title":"Cell Cycle"},{"key":"2760_CR3","doi-asserted-by":"publisher","first-page":"L1447","DOI":"10.1152\/ajplung.00262.2015","volume":"309","author":"EN Atochina-Vasserman","year":"2015","unstructured":"Atochina-Vasserman, E.N., Abramova, E., James, M.L., Rue, R., Liu, A.Y., Ersumo, N. T., Guo, C.J., Gow, A.J., and Krymskaya, V.P. (2015). Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol 309, L1447\u2013L1454.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2760_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.202007-2854OC","volume":"204","author":"R Babaei-Jadidi","year":"2021","unstructured":"Babaei-Jadidi, R., Dongre, A., Miller, S., Castellanos Uribe, M., Stewart, I.D., Thompson, Z.M., Nateri, A.S., Bradding, P., May, S.T., Clements, D., et al. (2021). Mast-cell tryptase release contributes to disease progression in lymphangioleiomyomatosis. Am J Respir Crit Care Med 204, 431\u2013444.","journal-title":"Am J Respir Crit Care Med"},{"key":"2760_CR5","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A.T., Thomas, G., Kozma, S.C., et al. (2008). Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118, 3065\u20133074.","journal-title":"J Clin Invest"},{"key":"2760_CR6","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1038\/onc.2008.247","volume":"27","author":"A Carracedo","year":"2008","unstructured":"Carracedo, A., and Pandolfi, P.P. (2008). The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27, 5527\u20135541.","journal-title":"Oncogene"},{"key":"2760_CR7","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1073\/pnas.97.11.6085","volume":"97","author":"T Carsillo","year":"2000","unstructured":"Carsillo, T., Astrinidis, A., and Henske, E.P. (2000). Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 97, 6085\u20136090.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2760_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000515816","volume":"58","author":"L Chen","year":"2021","unstructured":"Chen, L., Dai, L., Yan, D., Zhou, B., Zheng, W., Yin, J., Zhou, T., Liu, Z., Deng, J., Wang, R., et al. (2021). Gleevec and rapamycin synergistically reduce cell viability and inhibit proliferation and angiogenic function of mouse bone marrow-derived endothelial progenitor cells. J Vasc Res 58, 330\u2013342.","journal-title":"J Vasc Res"},{"key":"2760_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41401-022-00940-4","volume":"44","author":"S Chen","year":"2023","unstructured":"Chen, S., Zhao, C., Yao, L., Wang, L., Ma, Y., Meng, L., Cai, S., Liu, C., Qu, L., Jia, Y., et al. (2023). Aiphanol, a multi-targeting stilbenolignan, potently suppresses mouse lymphangiogenesis and lymphatic metastasis. Acta Pharmacol Sin 44, 189\u2013200.","journal-title":"Acta Pharmacol Sin"},{"key":"2760_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/mc.20628","volume":"49","author":"X Chen","year":"2010","unstructured":"Chen, X., Liu, F., Song, X., Wang, Z., Dong, Z., Hu, Z., Lan, R., Guan, W., Zhou, T., Xu, X., et al. (2010). Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways. Mol Carcinog 49, 603\u2013610.","journal-title":"Mol Carcinog"},{"key":"2760_CR11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0968-0004(03)00193-2","volume":"28","author":"MJ Cross","year":"2003","unstructured":"Cross, M.J., Dixelius, J., Matsumoto, T., and Claesson-Welsh, L. (2003). VEGF-receptor signal transduction. Trends Biochem Sci 28, 488\u2013494.","journal-title":"Trends Biochem Sci"},{"key":"2760_CR12","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.3390\/cells10051222","volume":"10","author":"A Dumond","year":"2021","unstructured":"Dumond, A., Montemagno, C., Vial, V., Gr\u00e9pin, R., and Pag\u00e8s, G. (2021). Anti-vascular endothelial growth factor C antibodies efficiently inhibit the growth of experimental clear cell renal cell carcinomas. Cells 10, 1222.","journal-title":"Cells"},{"key":"2760_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/biom10010028","volume":"10","author":"JF Evans","year":"2019","unstructured":"Evans, J.F., Rue, R.W., Mukhitov, A.R., Obraztsova, K., Smith, C.J., and Krymskaya, V. P. (2019). Inhibition of growth of TSC2-null cells by a PI3K\/mTOR inhibitor but not by a selective MNK1\/2 inhibitor. Biomolecules 10, 28.","journal-title":"Biomolecules"},{"key":"2760_CR14","first-page":"3406","volume":"17","author":"H Gao","year":"2011","unstructured":"Gao, H., Zhang, J., Liu, T., and Shi, W. (2011). Rapamycin prevents endothelial cell migration by inhibiting the endothelial-to-mesenchymal transition and matrix metalloproteinase-2 and -9: an in vitro study. Mol Vis 17, 3406\u20133414.","journal-title":"Mol Vis"},{"key":"2760_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1755-8794-3-21","volume":"3","author":"A Gribov","year":"2010","unstructured":"Gribov, A., Sill, M., L\u00fcck, S., R\u00fccker, F., D\u00f6hner, K., Bullinger, L., Benner, A., and Unwin, A. (2010). SEURAT: visual analytics for the integrated analysis of microarray data. BMC Med Genomics 3, 21.","journal-title":"BMC Med Genomics"},{"key":"2760_CR16","doi-asserted-by":"publisher","first-page":"e230312","DOI":"10.1530\/ERC-23-0312","volume":"31","author":"E Gibbons","year":"2024","unstructured":"Gibbons, E., Taya, M., Wu, H., Lopa, S.H., Moss, J., Henske, E.P., McCormack, F.X., and Hammes, S.R. (2024). Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis. Endocr Relat Cancer 31, e230312.","journal-title":"Endocr Relat Cancer"},{"key":"2760_CR17","doi-asserted-by":"publisher","first-page":"14960","DOI":"10.1073\/pnas.1309110110","volume":"110","author":"X Gu","year":"2013","unstructured":"Gu, X., Yu, J.J., Ilter, D., Blenis, N., Henske, E.P., and Blenis, J. (2013). Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis. Proc Natl Acad Sci USA 110, 14960\u201314965.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2760_CR18","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1164\/rccm.201912-2445OC","volume":"202","author":"M Guo","year":"2020","unstructured":"Guo, M., Yu, J.J., Perl, A.K., Wikenheiser-Brokamp, K.A., Riccetti, M., Zhang, E.Y., Sudha, P., Adam, M., Potter, A., Kopras, E.J., et al. (2020). Single-cell transcriptomic analysis identifies a unique pulmonary lymphangioleiomyomatosis cell. Am J Respir Crit Care Med 202, 1373\u20131387.","journal-title":"Am J Respir Crit Care Med"},{"key":"2760_CR19","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1097\/PAS.0b013e318235edbd","volume":"35","author":"T Hayashi","year":"2011","unstructured":"Hayashi, T., Kumasaka, T., Mitani, K., Terao, Y., Watanabe, M., Oide, T., Nakatani, Y., Hebisawa, A., Konno, R., Takahashi, K., et al. (2011). Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: a clinicopathologic study of 10 patients. Am J Surg Pathol 35, 1776\u20131785.","journal-title":"Am J Surg Pathol"},{"key":"2760_CR20","doi-asserted-by":"publisher","first-page":"D870","DOI":"10.1093\/nar\/gkac947","volume":"51","author":"C Hu","year":"2023","unstructured":"Hu, C., Li, T., Xu, Y., Zhang, X., Li, F., Bai, J., Chen, J., Jiang, W., Yang, K., Ou, Q., et al. (2023). CellMarker 2.0: an updated database of manually curated cell markers in human\/mouse and web tools based on scRNA-seq data. Nucleic Acids Res 51, D870\u2013D876.","journal-title":"Nucleic Acids Res"},{"key":"2760_CR21","doi-asserted-by":"publisher","first-page":"919","DOI":"10.4161\/cbt.9.11.11805","volume":"9","author":"A Jaeger-Lansky","year":"2010","unstructured":"Jaeger-Lansky, A., Cejka, D., Ying, L., Preusser, M., Hoeflmayer, D., Fuereder, T., Koehrer, S., and Wacheck, V. (2010). Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo. Cancer Biol Ther 9, 919\u2013927.","journal-title":"Cancer Biol Ther"},{"key":"2760_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccr.2011.12.026","volume":"21","author":"T Karnezis","year":"2012","unstructured":"Karnezis, T., Shayan, R., Caesar, C., Roufail, S., Harris, N.C., Ardipradja, K., Zhang, Y. F., Williams, S.P., Farnsworth, R.H., Chai, M.G., et al. (2012). VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 21, 181\u2013195.","journal-title":"Cancer Cell"},{"key":"2760_CR23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1097\/01.pas.0000126859.70814.6d","volume":"28","author":"T Kumasaka","year":"2004","unstructured":"Kumasaka, T., Seyama, K., Mitani, K., Sato, T., Souma, S., Kondo, T., Hayashi, S., Minami, M., Uekusa, T., Fukuchi, Y., et al. (2004). Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleio-myomatosis. Am J Surg Pathol 28, 1007\u20131016.","journal-title":"Am J Surg Pathol"},{"key":"2760_CR24","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1097\/01.pas.0000172192.25295.45","volume":"29","author":"T Kumasaka","year":"2005","unstructured":"Kumasaka, T., Seyama, K., Mitani, K., Souma, S., Kashiwagi, S., Hebisawa, A., Sato, T., Kubo, H., Gomi, K., Shibuya, K., et al. (2005). Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol 29, 1356\u20131366.","journal-title":"Am J Surg Pathol"},{"key":"2760_CR25","doi-asserted-by":"publisher","first-page":"105098","DOI":"10.1016\/j.ejps.2019.105098","volume":"142","author":"E Landh","year":"2020","unstructured":"Landh, E., Moir, L.M., Gomes Dos Reis, L., Traini, D., Young, P.M., and Ong, H.X. (2020). Inhaled rapamycin solid lipid nano particles for the treatment of lymphangioleiomyomatosis. Eur J Pharm Sci 142, 105098.","journal-title":"Eur J Pharm Sci"},{"key":"2760_CR26","doi-asserted-by":"publisher","first-page":"e86629","DOI":"10.1172\/jci.insight.86629","volume":"1","author":"C Li","year":"2016","unstructured":"Li, C., Li, N., Liu, X., Zhang, E.Y., Sun, Y., Masuda, K., Li, J., Sun, J., Morrison, T., Li, X., et al. (2016). Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis. JCI Insight 1, e86629.","journal-title":"JCI Insight"},{"key":"2760_CR27","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.bbrc.2015.09.031","volume":"466","author":"WD Li","year":"2015","unstructured":"Li, W.D., Hu, N., Lei, F.R., Wei, S., Rong, J.J., Zhuang, H., and Li, X.Q. (2015). Autophagy inhibits endothelial progenitor cells migration via the regulation of MMP2, MMP9 and uPA under normoxia condition. Biochem Biophys Res Commun 466, 376\u2013380.","journal-title":"Biochem Biophys Res Commun"},{"key":"2760_CR28","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S2213-2600(21)00228-9","volume":"9","author":"C McCarthy","year":"2021","unstructured":"McCarthy, C., Gupta, N., Johnson, S.R., Yu, J.J., and McCormack, F.X. (2021). Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. Lancet Respir Med 9, 1313\u20131327.","journal-title":"Lancet Respir Med"},{"key":"2760_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2015.12.008","volume":"158","author":"LM Moir","year":"2016","unstructured":"Moir, L.M. (2016). Lymphangioleiomyomatosis: Current understanding and potential treatments. Pharmacol Ther 158, 114\u2013124.","journal-title":"Pharmacol Ther"},{"key":"2760_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1164\/ajrccm.186.4.389","volume":"186","author":"T Moua","year":"2012","unstructured":"Moua, T., Olson, E.J., Jean, H.C.S., and Ryu, J.H. (2012). Resolution of chylous pulmonary congestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy. Am J Respir Crit Care Med 186, 389\u2013390.","journal-title":"Am J Respir Crit Care Med"},{"key":"2760_CR31","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.2169\/internalmedicine.8645-16","volume":"56","author":"M Namba","year":"2017","unstructured":"Namba, M., Masuda, T., Nakamura, T., Horimasu, Y., Miyamoto, S., Nakashima, T., Iwamoto, H., Fujitaka, K., Hamada, H., and Hattori, N. (2017). Additional octreotide therapy to sirolimus achieved a decrease in sirolimus-refractory chylous effusion complicated with lymphangioleiomyomatosis. Intern Med 56, 3327\u20133331.","journal-title":"Intern Med"},{"key":"2760_CR32","doi-asserted-by":"publisher","first-page":"8406","DOI":"10.1038\/s41598-021-88064-3","volume":"11","author":"K Nishino","year":"2021","unstructured":"Nishino, K., Yoshimatsu, Y., Muramatsu, T., Sekimoto, Y., Mitani, K., Kobayashi, E., Okamoto, S., Ebana, H., Okada, Y., Kurihara, M., et al. (2021). Isolation and characterisation of lymphatic endothelial cells from lung tissues affected by lymphangioleiomyomatosis. Sci Rep 11, 8406.","journal-title":"Sci Rep"},{"key":"2760_CR33","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1210\/en.2016-1395","volume":"157","author":"H Prizant","year":"2016","unstructured":"Prizant, H., and Hammes, S.R. (2016). Minireview: lymphangioleiomyomatosis (LAM): the \u201cother\u201d steroid-sensitive cancer. Endocrinology 157, 3374\u20133383.","journal-title":"Endocrinology"},{"key":"2760_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1164\/rccm.200409-1298OC","volume":"173","author":"JH Ryu","year":"2006","unstructured":"Ryu, J.H., Moss, J., Beck, G.J., Lee, J.C., Brown, K.K., Chapman, J.T., Finlay, G.A., Olson, E.J., Ruoss, S.J., Maurer, J.R., et al. (2006). The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 173, 105\u2013111.","journal-title":"Am J Respir Crit Care Med"},{"key":"2760_CR35","doi-asserted-by":"publisher","first-page":"7760","DOI":"10.3390\/ijms22147760","volume":"22","author":"GA Secker","year":"2021","unstructured":"Secker, G.A., and Harvey, N.L. (2021). Regulation of VEGFR signalling in lymphatic vascular development and disease: an update. Int J Mol Sci 22, 7760.","journal-title":"Int J Mol Sci"},{"key":"2760_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/lrb.2009.0018","volume":"8","author":"K Seyama","year":"2010","unstructured":"Seyama, K., Kumasaka, T., Kurihara, M., Mitani, K., and Sato, T. (2010). Lymphangioleiomyomatosis: a disease involving the lymphatic system. Lymphat Res Biol 8, 21\u201331.","journal-title":"Lymphat Res Biol"},{"key":"2760_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1089\/lrb.2006.4.143","volume":"4","author":"K Seyama","year":"2006","unstructured":"Seyama, K., Kumasaka, T., Souma, S., Sato, T., Kurihara, M., Mitani, K., Tominaga, S., and Fukuchi, Y. (2006). Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 4, 143\u2013152.","journal-title":"Lymphat Res Biol"},{"key":"2760_CR38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11684-020-0812-7","volume":"15","author":"SY Sun","year":"2021","unstructured":"Sun, S.Y. (2021). mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why? Front Med 15, 221\u2013231.","journal-title":"Front Med"},{"key":"2760_CR39","doi-asserted-by":"publisher","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","volume":"65","author":"SY Sun","year":"2005","unstructured":"Sun, S.Y., Rosenberg, L.M., Wang, X., Zhou, Z., Yue, P., Fu, H., and Khuri, F.R. (2005). Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65, 7052\u20137058.","journal-title":"Cancer Res"},{"key":"2760_CR40","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1513\/AnnalsATS.201605-335OC","volume":"13","author":"T Takada","year":"2016","unstructured":"Takada, T., Mikami, A., Kitamura, N., Seyama, K., Inoue, Y., Nagai, K., Suzuki, M., Moriyama, H., Akasaka, K., Tazawa, R., et al. (2016). Efficacy and safety of long-term sirolimus therapy for Asian patients with lymphangioleiomyomatosis. Ann ATS 13, 1912\u20131922.","journal-title":"Ann ATS"},{"key":"2760_CR41","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.chest.2017.05.012","volume":"153","author":"AM Taveira-DaSilva","year":"2018","unstructured":"Taveira-DaSilva, A.M., Jones, A.M., Julien-Williams, P., Stylianou, M., and Moss, J. (2018). Long-term effect of sirolimus on serum vascular endothelial growth factor D levels in patients with lymphangioleiomyomatosis. Chest 153, 124\u2013132.","journal-title":"Chest"},{"key":"2760_CR42","doi-asserted-by":"publisher","first-page":"104397","DOI":"10.1016\/j.mvr.2022.104397","volume":"143","author":"JK Wolter","year":"2022","unstructured":"Wolter, J.K., Valencia-Sama, I., Osborn, A.J., Propst, E.J., Irwin, M.S., Papsin, B., and Wolter, N.E. (2022). Combination mTOR and SHP2 inhibitor treatment of lymphatic malformation endothelial cells. Microvasc Res 143, 104397.","journal-title":"Microvasc Res"},{"key":"2760_CR43","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T., Hu, E., Xu, S., Chen, M., Guo, P., Dai, Z., Feng, T., Zhou, L., Tang, W., Zhan, L., et al. (2021). clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141.","journal-title":"Innovation"},{"key":"2760_CR44","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2147\/TCRM.S50784","volume":"10","author":"KF Xu","year":"2014","unstructured":"Xu, K.F., and Lo, B.H. (2014). Lymphangioleiomyomatosis: differential diagnosis and optimal management. Ther Clin Risk Manag 10, 691\u2013700.","journal-title":"Ther Clin Risk Manag"},{"key":"2760_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.rmed.2012.10.006","volume":"107","author":"KF Xu","year":"2013","unstructured":"Xu, K.F., Zhang, P., Tian, X., Ma, A., Li, X., Zhou, J., Zeng, N., Gui, Y.S., Guo, Z., Feng, R., et al. (2013). The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med 107, 263\u2013268.","journal-title":"Respir Med"},{"key":"2760_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.chest.2023.02.026","volume":"164","author":"W Xu","year":"2023","unstructured":"Xu, W., Yang, C., Cheng, C., Wang, Y., Hu, D., Huang, J., He, Y., Wang, J., Chen, K., Yang, L., et al. (2023). Determinants of progression and mortality in lymphangioleiomyomatosis. Chest 164, 137\u2013148.","journal-title":"Chest"},{"key":"2760_CR47","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1056\/NEJMc0707517","volume":"358","author":"LR Young","year":"2008","unstructured":"Young, L.R., Inoue, Y., and McCormack, F.X. (2008). Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 358, 199\u2013200.","journal-title":"N Engl J Med"},{"key":"2760_CR48","doi-asserted-by":"publisher","first-page":"L694","DOI":"10.1152\/ajplung.00204.2003","volume":"286","author":"J Yu","year":"2004","unstructured":"Yu, J., Astrinidis, A., Howard, S., and Henske, E.P. (2004). Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol 286, L694\u2013L700.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2760_CR49","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1073\/pnas.0810790106","volume":"106","author":"JJ Yu","year":"2009","unstructured":"Yu, J.J., Robb, V.A., Morrison, T.A., Ariazi, E.A., Karbowniczek, M., Astrinidis, A., Wang, C., Hernandez-Cuebas, L., Seeholzer, L.F., Nicolas, E., et al. (2009). Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci USA 106, 2635\u20132640.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2760_CR50","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13023-018-0775-9","volume":"13","author":"Y Zhan","year":"2018","unstructured":"Zhan, Y., Shen, L., Xu, W., Wu, X., Zhang, W., Wang, J., Li, X., Yang, Y., Tian, X., and Xu, K.F. (2018). Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study. Orphanet J Rare Dis 13, 34.","journal-title":"Orphanet J Rare Dis"},{"key":"2760_CR51","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s13287-022-03132-3","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang, L., Ye, C., Li, P., Li, C., Shu, W., Zhao, Y., and Wang, X. (2022). ADSCs stimulated by VEGF-C alleviate intestinal inflammation via dual mechanisms of enhancing lymphatic drainage by a VEGF-C\/VEGFR-3-dependent mechanism and inhibiting the NF-\u03baB pathway by the secretome. Stem Cell Res Ther 13, 448.","journal-title":"Stem Cell Res Ther"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-024-2760-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-024-2760-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-024-2760-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:02:45Z","timestamp":1791399765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-024-2760-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2760"],"URL":"https:\/\/doi.org\/10.1007\/s11427-024-2760-4","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest. The single-cell data used in this study were derived from publicly available data (Guo et al., 2020). All human-related studies were approved by the ethics committee of the University of Cincinnati College of Medicine. The animal study was approved by the Animal Ethics Committee of Peking Union Medical College (XHDW-2022-121).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}